Evidence map›Paper›PMID 36316743›Full record

ReviewBMC medical genomics2022

Pigmentary mosaicism as a recurrent clinical manifestation in three new patients with mosaic trisomy 12 diagnosed postnatally: cases report and literature review.

A Martínez-Hernández, D Martínez-Anaya, C Durán-McKinster, V Del Castillo-Ruiz, P Navarrete-Meneses, E J Córdova, B E Villegas-Torres, A Ruiz-Herrera, R Juárez-Velázquez, E Yokoyama-Rebollar and 5 more

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in BMC medical genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

A Martínez-HernándezLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica SS, Ciudad de Mexico, México.
D Martínez-AnayaLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, 04530, México.
C Durán-McKinsterDepartamento de Dermatología, Instituto Nacional de Pediatría, Ciudad de Mexico, México.
V Del Castillo-RuizDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, México.
P Navarrete-MenesesLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, 04530, México.
E J CórdovaConsorcio de Oncogenómica, Instituto Nacional de Medicina Genómica SS, Ciudad de Mexico, México.
B E Villegas-TorresInstituto Nacional de Medicina Genómica SS, Ciudad de Mexico, México.
A Ruiz-HerreraHospital de Especialidades Pediátrico de León, León, Guanajuato, México.
R Juárez-VelázquezLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, 04530, México.
E Yokoyama-RebollarDepartamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, México.
D Cervantes-BarragánHospital Central Sur de Alta Especialidad, PEMEX, Ciudad de Mexico, México.
A Pedraza-MeléndezPosgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Ciudad de Mexico, México.
L OrozcoLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica SS, Ciudad de Mexico, México.
P Pérez-VeraLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, 04530, México. pperezvera@yahoo.com.
C Salas-LabadíaLaboratorio de Genética y Cáncer, Departamento de Genética Humana, Instituto Nacional de Pediatría, Ciudad de Mexico, 04530, México. csalasl@pediatria.gob.mx.ORCID 0000-0002-3301-7357
Instituto Nacional de Pediatria · MXNational Institute of Genomic Medicine · MXHospital de Especialidades · MXPemex (Mexico) · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, only twenty-one cases diagnosed postnatally with mosaic trisomy 12 have been reported. The most frequent phenotypic manifestations are developmental delay, dysmorphic facial features, congenital heart defects, digital alterations, and pigmentary disorders. In the present report, detailed clinical and genetic profiles of three unrelated new patients with mosaic trisomy 12 are described and compared with previously reported cases. CASE PRESENTATION: In the present report, we include the clinical, cytogenetic, and molecular description of three Mexican patients diagnosed postnatally with mosaic trisomy 12. At phenotypic level, the three patients present with developmental delay, dysmorphic facial features, congenital heart defects and skin pigmentary anomalies. Particularly, patient 1 showed unique eye alterations as bilateral distichiasis, triple rows of upper lashes, and digital abnormalities. In patient 2 redundant skin, severe hearing loss, and hypotonia were observed, and patient 3 presented with hypertelorism and telecanthus. Hyperpigmentation with disseminated pigmentary anomalies is a common trait in all of them. The cytogenetic study was carried out under the strict criteria of analysis, screening 50-100 metaphases from three different tissues, showing trisomy 12 mosaicism in at least one of the three different tissues analyzed. With SNParray, the presence of low-level mosaic copy number variants not previously detected by cytogenetics, and uniparental disomy of chromosome 12, was excluded. STR markers allowed to confirm the absence of uniparental disomy as well as to know the parental origin of supernumerary chromosome 12.

conclusionsThe detailed clinical, cytogenetic, and molecular description of these three new patients, contributes with relevant information to delineate more accurately a group of patients that show a heterogeneous phenotype, although sharing the same chromosomal alteration. The possibility of detecting mosaic trisomy 12 is directly associated with the sensitivity of the methodology applied to reveal the low-level chromosomal mosaicism, as well as with the possibility to perform the analysis in a suitable tissue.

Indexed as

Chromosome DisordersTrisomyCytogenetic AnalysisHumansMosaicismUniparental DisomyBlaschko linesCase reportLow-level mosaicismMosaic trisomy 12Pigmentary mosaicismSNP arrayUniparental disomy 12

Identifiers

PMID36316743
PMCPMC9620619
OpenAlexW4307885585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.